Platelet surface marker response of ITP patient platelets to in vitro agonist stimulation
| . | No agonist . | ADP 0.5 µM . | ADP 20 µM . | TRAP 1.5 µM . | TRAP 20 µM . |
|---|---|---|---|---|---|
| Activated GPIIb-IIIa, % PAC1- positive | 38.5 (15.8, 52.2) | 93.2 (86.5, 96.9) | 97.8 (95.7, 98.5) | 95.2 (65.3, 97.3) | 97.8 (95.1, 98.8) |
| P-selectin, % positive | 14.7 (8.8, 25.8) | 67.4 (57.0, 80.7) | 93.1 (87.4, 97.4) | 88.4 (61.6, 97.4) | 98.8 (96.9, 99.3) |
| Activated GPIIb-IIIa, PAC1 MFI | 8.1 (5.1, 11.7) | 103.6 (54.8, 182.9) | 275.8 (189.8, 414.6) | 103.5 (30.5, 214.1) | 269.2 (154.5, 422.6) |
| P-selectin, MFI | 5.8 (4.9, 7.7) | 36.6 (22.5, 51.3) | 114.6 (82.0, 207.6) | 79.5 (32.6, 210.3) | 417.3 (335.9, 504.0) |
| GPIb, MFI | 298.4 (244.1, 346.3) | 227.8 (205.5, 282.8) | 220.7 (190.3, 248.3) | 239.0 (192.0, 303.5) | 171.9 (149.8, 225.5) |
| . | No agonist . | ADP 0.5 µM . | ADP 20 µM . | TRAP 1.5 µM . | TRAP 20 µM . |
|---|---|---|---|---|---|
| Activated GPIIb-IIIa, % PAC1- positive | 38.5 (15.8, 52.2) | 93.2 (86.5, 96.9) | 97.8 (95.7, 98.5) | 95.2 (65.3, 97.3) | 97.8 (95.1, 98.8) |
| P-selectin, % positive | 14.7 (8.8, 25.8) | 67.4 (57.0, 80.7) | 93.1 (87.4, 97.4) | 88.4 (61.6, 97.4) | 98.8 (96.9, 99.3) |
| Activated GPIIb-IIIa, PAC1 MFI | 8.1 (5.1, 11.7) | 103.6 (54.8, 182.9) | 275.8 (189.8, 414.6) | 103.5 (30.5, 214.1) | 269.2 (154.5, 422.6) |
| P-selectin, MFI | 5.8 (4.9, 7.7) | 36.6 (22.5, 51.3) | 114.6 (82.0, 207.6) | 79.5 (32.6, 210.3) | 417.3 (335.9, 504.0) |
| GPIb, MFI | 298.4 (244.1, 346.3) | 227.8 (205.5, 282.8) | 220.7 (190.3, 248.3) | 239.0 (192.0, 303.5) | 171.9 (149.8, 225.5) |
Results shown are medians (IQR), n = 41. Each platelet marker was significantly altered by in vitro stimulation (P < .0001, 2-sided nonparametric analysis of variance; P < .05 for each agonist compared with “No Agonist”; Dunn’s multiple comparison test).
MFI, geometric mean fluorescence intensity.